Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis

Documenti analoghi

• Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
  di: Bruce Strober, et al.
  Pubblicazione: (2024)
• Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema
  di: Diamant Thaçi, et al.
  Pubblicazione: (2025)
• Dysregulation of epigenetic, biological and mitotic age in the context of biologic drug treatment and phototherapy in plaque psoriasis patients
  di: Richie Jeremian, et al.
  Pubblicazione: (2024)
• Reply to ‘Delayed absorption and systemic variability of topical delgocitinib in Chronic Hand Eczema’
  di: Diamant Thaçi, et al.
  Pubblicazione: (2025)
• Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years
  di: Melinda J. Gooderham, et al.
  Pubblicazione: (2026)